Müllerian inhibiting substance as a novel biomarker of cisplatin-induced ovarian damage
- 1 September 2006
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 348 (2), 337-344
- https://doi.org/10.1016/j.bbrc.2006.06.195
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Understanding the menopausal transition, and managing its clinical challengesSexuality, Reproduction and Menopause, 2005
- Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testingHuman Reproduction Update, 2005
- Aging and infertility in womenFertility and Sterility, 2004
- Effects of cyclophosphamide and buthionine sulfoximine on ovarian glutathione and apoptosisFree Radical Biology & Medicine, 2004
- Bcl-xES, a BH4- and BH2-containing antiapoptotic protein, delays Bax oligomer formation and binds Apaf-1, blocking procaspase-9 activationOncogene, 2004
- Supporting Cells As a Target of Cisplatin‐Induced Inner Ear Damage: Therapeutic ImplicationsThe Laryngoscope, 2004
- Menstrual and Hormone Patterns in Women Treated with High-Dose Cisplatin and BleomycinGynecologic Oncology, 1994
- Comparison of random and serial sections in assessment of ovarian toxicityReproductive Toxicology, 1991
- The short-term reproductive toxicity of cyclophosphamide in the female ratReproductive Toxicology, 1991
- An evaluation of the serum FSH as a biomarker for ovarian toxicity in the ratReproductive Toxicology, 1988